 | Today's Top Story |  |  | | | Health Care & Policy | | | | - Merck's overactive bladder OTC drug wins FDA approval
Merck & Co. obtained FDA approval to market an over-the-counter version of Oxytrol for women ages 18 and older with overactive bladder. The OTC product, which will be sold as Oxytrol for Women, is a patch that contains oxybutynin, an anticholinergic agent that helps relax the bladder muscle. Men will continue to need a prescription to buy the drug, FDA says. Reuters (1/25), MedPage Today (free registration) (1/25)       - FDA expands approval for childhood leukemia drug
The FDA approved Friday the expanded use of Novartis' leukemia drug Gleevec to include children newly diagnosed with Philadelphia chromosome positive acute lymphoblastic leukemia. The drug should be combined with chemotherapy and carries a risk of several adverse reactions, including liver toxicity and infections, the agency said. Bloomberg Businessweek (1/25) - Takeda gains FDA OK for 3 formulations of type 2 diabetes drug
The FDA has granted Takeda Pharmaceuticals approval for its type 2 diabetes drug alogliptin as a standalone medication, and as an add-on to metformin in its Kazano formulation and with pioglitazone under the name Oseni. Alogliptin by itself will be branded as Nesina. Reuters (1/25) - Opinion: Develop incentives for better vaccines against the flu
Governments should get large drugmakers involved in developing future flu vaccines, according to this editorial. The U.S. government should provide incentives and urge other nations with manufacturing means to follow. Possibilities that should be considered include monetary rewards for breakthroughs, extensions of market exclusivity and patents, fast-track reviews, and tax incentives for research and development. Bloomberg Businessweek (1/24) | Company & Financial News | | | | | Food & Agriculture | | | | - Viral gene in biotech plants poses no health risks, EFSA panel chair says
The viral gene found in biotech plants has no safety implications because it belongs to a plant virus that cannot infect humans or animals, according to Joe Perry, chairman of a European Food Safety Authority panel. "All GMO applications containing the inserted fragment of the viral gene in question, which have been assessed by the EFSA Panel since its creation in 2002, have included a detailed analysis of the inserted sequence," he said. FarmingUK (1/25), Food Poisoning Bulletin (1/23) | Hot Topics | | | | Top five news stories selected by BIO SmartBrief readers in the past week. - Results based on number of times each story was clicked by readers.
| Industrial & Environmental | | | | - Appeals court was mostly favorable to RFS, biofuel groups say
The U.S. Court of Appeals for the District of Columbia vacated the 2012 cellulosic biofuel requirement under the Renewable Fuel Standard but dismissed several other petitions by the oil industry to undermine the RFS, according to BIO and other biofuel industry groups. "[A]lthough we disagree with the court's decision vacating the 2012 cellulosic volumes, today's decision once again rejects broad-brushed attempts to effectively roll back the federal Renewable Fuel Standard," the groups said. DomesticFuel.com (1/25), Politico (Washington, D.C.) (1/28) | News from BIO | | | | - Are you taking full advantage of your membership?
BIO's cost-savings program, BIO Business Solutions, is helping 2,700 companies nationwide save on the cost of essential products and services. Members of BIO and 43 state and regional biotech associations are eligible to receive preferential pricing and other benefits at no additional cost beyond their membership dues. VWR International, FedEx, Office Depot and Business Wire are just a few of the industry leading providers that offer special pricing through this members-only program. Learn more or enroll here.
| SmartQuote | | | |  | If fate means you to lose, give him a good fight anyhow."
--William McFee,
British-American writer  |
| | This SmartBrief was created for jmabs1@gmail.com
| | | Read more at SmartBrief.com | | A powerful website for SmartBrief readers including: | | | | | | | | | | Recent BIO SmartBrief Issues: - Friday, January 25, 2013
- Thursday, January 24, 2013
- Wednesday, January 23, 2013
- Tuesday, January 22, 2013
- Monday, January 21, 2013
| | | Lead Editor: Tom Parks
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004 | | | | | | © 1999-2013 SmartBrief, Inc.® Legal Information |
|
No comments:
Post a Comment